<DOC>
	<DOCNO>NCT00004068</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining chemotherapy radiation therapy may kill tumor cell . PURPOSE : Phase II trial study effectiveness irinotecan follow radiation therapy temozolomide treat child newly diagnose brain tumor .</brief_summary>
	<brief_title>Irinotecan Followed Radiation Therapy Temozolomide Treating Children With Newly Diagnosed Brain Tumor</brief_title>
	<detailed_description>OBJECTIVES : - Evaluate efficacy adjuvant irinotecan child newly diagnose high grade glioma , brain stem glioma , high risk grade II astrocytomas term complete partial response rate patient postoperative measurable disease , term rate freedom recurrence patient postoperative measurable disease . - Determine 3 year overall progression free survival rate patient population treat adjuvant irinotecan follow radiotherapy temozolomide . - Assess hematopoietic toxicity temozolomide follow local radiotherapy patient population . OUTLINE : Patients receive postoperative irinotecan IV 60 minute daily 5 day week 1-2 . Treatment repeat every 3 week 2 course . Following completion irinotecan appropriate , patient may undergo second surgical resection . Within 2 week follow completion chemotherapy within 4 week follow second resection , patient receive image guide external beam radiotherapy 5 day per week 6 week . Patients residual tumor le 3.5 cm maximal diameter may undergo boost radiosurgery . At 4 week follow completion radiotherapy , patient receive oral temozolomide 5 day . Treatment repeat every 3 week 6 course . Patients follow every 3 month 2 year , every 4 month 3 year . PROJECTED ACCRUAL : A total 50 patient accrue study within 5 year .</detailed_description>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm newly diagnose brain tumor Grade III IV disease : Glioblastoma multiforme Anaplastic astrocytoma Anaplastic oligodendroglioma Anaplastic pleomorphic xanthoastrocytoma Anaplastic malignant oligoastrocytoma Gemistocytic astrocytoma Malignant glioma Grade II glial tumor unfavorable location ( i.e. , image evidence gliomatosis cerebri and/or bithalamic involvement ) Diffuse pontine glioma great 2/3 involvement pon PATIENT CHARACTERISTICS : Age : 3 21 Performance status : Not specify Life expectancy : Not specify Hematopoietic : WBC great 2,500/mm^3 Platelet count great 100,000/mm^3 Hemoglobin great 8.0 g/dL Hepatic : Bilirubin great 2.5 mg/dL SGOT/SGPT le 5 time normal Renal : Creatinine great 2.0 mg/dL Other : Not pregnant Negative pregnancy test Fertile patient must use effective contraception HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Prior corticosteroid allow Radiotherapy : No prior radiotherapy Surgery : No 28 day since prior definitive surgery brain tumor Other : Concurrent anticonvulsant allow</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>childhood high-grade cerebral astrocytoma</keyword>
	<keyword>childhood high-grade cerebellar astrocytoma</keyword>
	<keyword>childhood oligodendroglioma</keyword>
	<keyword>untreated childhood brain stem glioma</keyword>
	<keyword>untreated childhood cerebellar astrocytoma</keyword>
</DOC>